lipoprotein Antibody (F-8): sc-393971
- lipoprotein Antibody (F-8) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- raised against amino acids 1-216 representing full length lipoprotein of Streptococcus equi subsp. equi 4047 origin
- recommended for detection of lipoprotein of S. equi origin by WB, IP, IF and ELISA
- m-IgG Fc BP-HRP, m-IgG1 BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for lipoprotein Antibody (F-8) for WB applications. These reagents are now offered in bundles with lipoprotein Antibody (F-8) (see ordering information below).
QUICK LINKS
SEE ALSO...
Lipoprotein Antibody (F-8) is a mouse monoclonal IgG1 antibody that detects lipoprotein in Streptococcus equi by applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-lipoprotein antibody (F-8) plays a crucial role in understanding the pathogenic mechanisms of S. equi, particularly in its interaction with host immune responses. Lipoproteins are essential components of the bacterial cell envelope, contributing to the structural integrity and functionality of the membrane. Lipoproteins are involved in various processes, including nutrient transport, cell signaling, and immune evasion, making these proteins vital for the survival and virulence of the bacteria. The presence of lipoproteins on the surface of S. equi can trigger immune responses in the host, which is significant for developing vaccines and therapeutic strategies against strangles, a disease that poses a serious threat to equine health. Using lipoprotein monoclonal antibody (F-8) in research can provide insights into the role of lipoproteins in S. equi pathogenesis and potential targets for intervention.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
lipoprotein Antibody (F-8) References:
- Lipoprotein synthesis in mycobacteria. | Rezwan, M., et al. 2007. Microbiology (Reading). 153: 652-658. PMID: 17322184
- Lipoprotein subfractions and cardiovascular disease risk. | Krauss, RM. 2010. Curr Opin Lipidol. 21: 305-11. PMID: 20531184
- Lipoprotein (a). Heterogeneity and biological relevance. | Scanu, AM. and Fless, GM. 1990. J Clin Invest. 85: 1709-15. PMID: 2140835
- Lipoprotein-inspired nanoparticles for cancer theranostics. | Ng, KK., et al. 2011. Acc Chem Res. 44: 1105-13. PMID: 21557543
- Lipoprotein component associated with hepatitis C virus is essential for virus infectivity. | Shimizu, Y., et al. 2011. Curr Opin Virol. 1: 19-26. PMID: 22440563
- Lipoprotein (a) Evolution: Possible Benefits and Harm. Genetic and Non-Genetic Factors Influencing its Plasma Levels. | Kostakou, PM., et al. 2017. Curr Med Chem. 24: 969-978. PMID: 28117004
- Relationship between lipoproteins, thrombosis, and atrial fibrillation. | Ding, WY., et al. 2022. Cardiovasc Res. 118: 716-731. PMID: 33483737
- Moderate alcohol consumption and lipoprotein subfractions: a systematic review of intervention and observational studies. | Wilkens, TL., et al. 2022. Nutr Rev. 80: 1311-1339. PMID: 34957513
- Lipoprotein metabolism. An overview. | Shepherd, J. 1994. Drugs. 47 Suppl 2: 1-10. PMID: 7517827
- Lipoprotein heterogeneity and apolipoprotein B metabolism. | Packard, CJ. and Shepherd, J. 1997. Arterioscler Thromb Vasc Biol. 17: 3542-56. PMID: 9437204
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
lipoprotein Antibody (F-8) | sc-393971 | 200 µg/ml | $322.00 | |||
lipoprotein Antibody (F-8): m-IgG Fc BP-HRP Bundle | sc-538347 | 200 µg Ab; 10 µg BP | $361.00 | |||
lipoprotein Antibody (F-8): m-IgGκ BP-HRP Bundle | sc-535940 | 200 µg Ab; 40 µg BP | $361.00 | |||
lipoprotein Antibody (F-8): m-IgG1 BP-HRP Bundle | sc-545655 | 200 µg Ab; 20 µg BP | $361.00 |